Midterm Clinical Impacts of Biodegradable Polymer Everolimus-Eluting Stents Compared with Durable Polymer Everolimus-Eluting Stents: A 3-Year Propensity-Matched Study

Table 2

Clinical outcomes at 1 year and 3 years.


	No. of patients with at least one event (cumulative incidence)		value
	BP-EES N = 327	DP-EES N = 327	value

Until 1-year follow-up
Target lesion failure	6 (1.9%)	14 (4.3%)	0.07
Cardiac death	4 (1.3%)	7 (2.2%)	0.36
Target vessel myocardial infarction	0 (0%)	5 (1.6%)	0.02
Clinically indicated target lesion revascularization	2 (0.6%)	7 (2.2%)	0.10
Clinically indicated target vessel revascularization	6 (1.9%)	7 (2.2%)	0.79
Definite stent thrombosis	0 (0%)	4 (1.3%)	0.04

Until 3-years follow-up
Target lesion failure	14 (4.5%)	21 (6.5%)	0.23
Cardiac death	4 (1.3%)	8 (2.5%)	0.24
Target vessel myocardial infarction	0 (0%)	6 (1.9%)	0.01
Clinically indicated target lesion revascularization	10 (3.2%)	13 (4.1%)	0.53
Clinically indicated target vessel revascularization	23 (7.5%)	17 (5.5%)	0.33
Definite stent thrombosis	0 (0%)	5 (1.6%)	0.02

Landmark analysis between 1–3 year
Target lesion failure	8 (2.6%)	7 (2.3%)	0.77
Cardiac death	0 (0%)	1 (0.3%)	0.31
Target vessel myocardial infarction	0 (0%)	1 (0.3%)	0.32
Clinically indicated target lesion revascularization	8 (2.6%)	6 (1.9%)	0.56
Clinically indicated target vessel revascularization	17 (5.6%)	10 (3.2%)	0.16
Definite stent thrombosis	0 (0%)	1 (0.3%)	0.32